Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Overview
Stock Information
Nasdaq:
COCPPrice
Change
Mkt Cap
Volume
52 week Low/High
Day Low/High